Effective drug against multiple sclerosis may now increase in price
Alemtuzumab is used most frequently in cancer, leukemia patients
Alemtuzumab is a new drug is the "most effective" treatment for relapsing-remitting multiple sclerosis. Researchers at the University of Cambridge say that alemtuzumab, a cancer drug, which wipes out and resets the immune system, has better results than other options. The down side? There is new concern that the drugs company that manufactures the medication is about to increase the cost of the drug as a result.
'There is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients and health systems,' an editorial in the medical journal the Lancet warns.
Alemtuzumab has shown benefits for MS in small studies. Typically used for leukemia patients, a blood cancer, controls the excess production of white blood cells. In MS patients, the dose eliminates the immune cells entirely, forcing a new immune system to be built from scratch which should not attack the nerves.
Two test trials compared the effectiveness of alemtuzumab with a first-choice drug, interferon beta-1a.
One compared the effectiveness in patients given the drug after being diagnosed, the other looked at patients given the drug after other treatments had failed.
Both showed the drug was around 50 percent more effective at preventing relapses and patients had less disability at the end of the study than when they started.
"Although other MS drugs have emerged over the last year, which is certainly good news for patients, none has shown superior effects on disability when compared to interferon except alemtuzumab," Dr. Alasdair Coles, from the University of Cambridge says.
"It is certainly the most effective MS drug, based on these clinical trials, but this is definitely not a cure," he told reporters from the BBC.
The doctor warns that there were side-effects, including developing other immune disorders.
He said he thought the drug would be most useful for patients for whom standard treatment had failed and in a "minority" of patients as a first-choice drug.
The drug has been withdrawn from the market in both Europe and the United States as the manufacturer, Genzyme, intends to have it licensed as a treatment for MS.
"There is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients and health systems," an editorial in the medical journal the Lancet warns.
"Finding promising treatments such as alemtuzumab are important. But so is keeping alemtuzumab accessible and affordable."
© 2012, Catholic Online. Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Alemtuzumab, multiple sclerosis, leukemia, cancer, price hike
Rate This Article
Leave a Comment
More Health News
- New studies reveal more information about autism cause
- Scientists discover why cancer spreads in human body
- Generic drugs to be more readily available after court ruling
- If you don't stop it -- you'll go blind! Sick sexual fetish can be dangerous, doctors warn
- HIV BREAKTHROUGH: New AIDS prevention pill may cut infection rates in IV drug users by 50 percent
- Brestfeeding baby has benefits for mom too!
- Blood test may one day replace colonoscopy
- Man suing plastic surgeon after he awakes with NO NOSE
- Federal officials issue warning about MERS, may be spread by Muslim pilgrimage
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?